Another major announcement – the second in less than three months – signals more remarkable growth for the City of Blair and the Greater Omaha region.
Evonik and Royal DSM announced on Thursday their plans to open a joint manufacturing venture – called Veramaris – in Blair on the Cargill campus. The $200 million facility will produce an innovative, new omega-3 fatty acid.
Venture partner Evonik is a known commodity in the community. The Germany-based company has been operating its own amino acid production facility in Blair for almost 20 years. The new commercial-scale plant, expected to be operational in 2019, will be located adjacent to Evonik’s current facility.
Lisa Scheve, executive director of Gateway Development Corp., a member of the Greater Omaha Chamber Economic Development Partnership, has been working with Evonik the past three years to encourage expansion in Blair.
“This has been a collaborative and global effort, up to and including our trip to Germany last year to meet with company representatives, underscore Evonik’s track record of success in our region, and move this new project forward,” Scheve said.
Randy Thelen, senior vice-president of economic development for the Greater Omaha Chamber, said, “The Cargill campus has proven to be an incredible asset for our region, its biotech industry and companies around the globe. We look forward to helping Veramaris thrive there, and we join our partners in congratulating Evonik and Royal DSM on the launch of this new venture.
The Veramaris announcement follows April’s news that international biotech company Evolva is planning to grow its global operation in collaboration with Cargill’s campus. The Switzerland-based company develops, makes and sells high-value specialty ingredients, including stevia, nootkatone and resveratrol.
For more background on Thursday’s Veramaris announcement: